SuperworthBioNexus Gene Lab shares outstanding BGLC
Diluted shares outstanding, averaged over each quarter, from 2018.
- Latest quarter, to Jun 30, 2026
- 2.4M
- On a year earlier
- +34.5%
- more shares
BioNexus Gene Lab had 2.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 34.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2022 | 1.4M | +1% |
| FY2021 | 1.4M | +65% |
| FY2020 | 862.3K | −1% |
| FY2019 | 870.2K | +65% |
| FY2018 | 527.1K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 2.4M | +35% | |
| Q1 FY26 | 2.4M | +35% | |
| Q3 FY25 | 1.8M | −0% | |
| Q2 FY25 | 1.8M | +2% | |
| Q1 FY25 | 1.8M | −90% | |
| Q3 FY24 | 1.8M | n/a | |
| Q2 FY24 | 1.8M | −90% | |
| Q1 FY24 | 17.7M | +1120% | |
| Q2 FY23 | 17.4M | +0% | |
| Q1 FY23 | 1.4M | +1% | |
| Q4 FY22 | 1.4M | +1% | |
| Q3 FY22 | 1.4M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on BioNexus Gene Lab
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.